Targeted therapy shows particular promise, especially when using 177Lu‐DOTATATE against NETs.[137,138] Similar success appears in treatments using 177Lu‐PSMA for prostate cancer and 131I for thyroid cancer.[139,140] RPhs enable crucial cardiac imaging for assessing cardiovascular function. Here, FOLH1 is linked to prostate carcinoma.